LIVN LivaNova Plc

LivaNova to Present at the Goldman Sachs Healthcare Conference

LONDON--(BUSINESS WIRE)--

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Goldman Sachs Healthcare Conference in Miami, Florida. The presentation will take place at 1:20 p.m. Eastern Time on Monday, June 10.

The discussion will be available to all interested parties who register to attend the webcast, which is accessible via . Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the webcast. A replay will be available on the LivaNova website within 24 hours after the live presentation for 90 days after the event.

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing solutions in select neurological and cardiac conditions. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit .

Safe Harbor Statement

This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding participation in upcoming events. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

EN
23/05/2024

Underlying

LIVNLivaNova Plc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LivaNova Plc

 PRESS RELEASE
Free
LIVN LIVANOVA PLC

LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Ther...

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the preliminary results for the unipolar patient cohort of the , assessing the use of VNS Therapy™ in treatment-resistant depression. The study did not meet its primary endpoint (PE) for the unipolar cohort; however, statistical significance was achieved in select secondary endpoints. The PE measured the difference between active and sham VNS Therapy on the rate of Montgomery–Åsberg Depression Rating Scale (MADRS) response for the unipolar patient cohort with a predetermined p-...

June 6, 2024 1 EN
 PRESS RELEASE
Free
LIVN LIVANOVA PLC

LivaNova to Present at the Goldman Sachs Healthcare Conference

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Goldman Sachs Healthcare Conference in Miami, Florida. The presentation will take place at 1:20 p.m. Eastern Time on Monday, June 10. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via . Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the webcast. A replay will be available on the L...

May 23, 2024 1 EN
 PRESS RELEASE
Free
LIVN LIVANOVA PLC

LivaNova Reports First-Quarter 2024 Results

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights(1) First-quarter revenue of $294.9 million increased 12.0% on a reported basis and 12.4% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 13.5% on a constant-currency basis First-quarter U.S. GAAP...

May 1, 2024 1 EN
 PRESS RELEASE
Free
LIVN LIVANOVA PLC

LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024. In this newly created position, Tezel will leverage his career of more than 20 years in research and development (R&D) to establish an integrated innovation function at LivaNova that will accelerate the Company’s development of new technologies. In this capacity, Tezel will join the LivaNova Executive Leadership Team. “I am very pleased to welcome Ahmet to the LivaNova team. At...

April 30, 2024 1 EN
 PRESS RELEASE
Free
LIVN LIVANOVA PLC

LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incide...

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that its wholly-owned U.S. subsidiary, LivaNova USA, Inc., is providing notice to U.S. patients regarding a cybersecurity incident that was initially disclosed by the Company on November 20, 2023. The incident resulted in a disruption to portions of the Company’s information technology systems. Promptly after detecting the issue on November 19, 2023, LivaNova began an investigation with assistance from external cybersecurity experts and coordinated with law enforcement. The Com...

April 25, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch